Osimertinib in Resected EGFR-Mutated NSCLC. Reply
- PMID: 37792623
- DOI: 10.1056/NEJMc2309385
Osimertinib in Resected EGFR-Mutated NSCLC. Reply
Comment on
-
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous